Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) belongs to Healthcare sector. Its weekly performance is 60.43%. On last trading day company shares ended up $3.69. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is 40.09%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), announced positive final results from a Phase II investigator sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema secondary to branch (BRVO) and central retinal vein occlusion (CRVO).
Synthetic Biologics Inc. (NYSEMKT:SYN) shares advanced 14.80% in last trading session and ended the day at $3.49. SYN return on assets is -242.70%. Synthetic Biologics Inc. (NYSEMKT:SYN) quarterly performance is 53.74%. On 29 June, Synthetic Biologics Inc., (NYSEMKT:SYN) reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).
On 13 July, Sequenom Inc. (NASDAQ:SQNM) shares advanced 7.80% and was closed at $3.18. SQNM EPS growth in last 5 year was 36.40%. Sequenom Inc. (NASDAQ:SQNM) year to date (YTD) performance is -14.05%. Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), announced the upcoming launch of the MaterniT™ GENOME laboratory-developed test. This test is the first noninvasive prenatal test (NIPT) to provide karyotype-level insight into fetal chromosomal status prior to considering an invasive procedure.
Kite Pharma, Inc. (NASDAQ:KITE) ended the last trading day at $69.78. Company weekly volatility is calculated as 5.78% and price to cash ratio as 7.01. Kite Pharma, Inc. (NASDAQ:KITE) showed a weekly performance of 6.84%. On 1st July, Kite Pharma, Inc., (NASDAQ:KITE) and The Leukemia & Lymphoma Society (LLS) announced that they have entered into a partnership to enhance the development of Kite’s lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL).
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) shares advanced 7.08% in last trading session and ended the day at $18.30. SRNE Gross Margin is 47.40% and its return on assets is -28.70%. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) quarterly performance is 52.12%. On 9 July, Sorrento Therapeutics, Inc. (NASDAQ:SRNE) and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of ‘first-in-class’ small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.